摘要
目的观察安罗替尼在经过多线化疗后进展的晚期卵巢癌治疗中的疗效和不良反应。方法 15例经病理确诊的经过至少3个方案的化疗后进展的晚期卵巢癌患者,给予安罗替尼治疗。统计分析患者的疗效及不良反应发生情况。结果末次随访时间为2019年7月6日,部分缓解(PR)3例,疾病稳定(SD)6例,疾病进展(PD)6例,总有效率(ORR)为20.0%,疾病控制率(DCR)为60.0%。中位无进展生存时间(PFS)为3.5个月, 95%CI=(2.4, 4.5),总生存期(OS)未达到。15例患者中疲劳和食欲减退的发生率均为100%, 2例达3级,减量至8 mg/d后降至1级;有2例2级患者要求减量至10 mg/d,减量后降至1级。高血压的发生率为33.3%,均为1、2级。肢体疼痛、口腔黏膜炎、腹泻和谷丙转氨酶(ALT)增高的发生率分别为13.3%、13.3%、6.7%、13.3%。结论安罗替尼对多线化疗后进展的晚期卵巢癌有一定疗效,通过调整剂量,不良反应可以耐受。
Objective To observe the efficacy and adverse reactions of anlotinib in the treatment of advanced ovarian cancer after multi-line chemotherapy. Methods A total of 15 patients with pathologically confirmed advanced ovarian cancer who had progressed after at least 3 regimens of chemotherapy were given anlotinib for treatment. The efficacy and occurrence of adverse reactions of patients were statistically analyzed. Results The last follow-up time was July 6, 2019. There were 3 cases of partial response(PR), 6 cases of stable disease(SD), 6 cases of progression of disease(PD), and the overall response rate(ORR) was 20.0%, disease control rate(DCR) was 60.0%. The median progression-free survival(PFS) was 3.5 months, 95%CI=(2.4, 4.5), and overall survival(OS) was not reached. The incidence of fatigue and loss of appetite were all 100% in 15 patients, 2 patients reached level 3, and reduced to level 1 after reducing to 8 mg/d;2 patients in level 2 required a reduction to 10 mg/d, and reduced to level 1 after reduction. The incidence of hypertension was 33.3%, both of stage 1 and stage 2. The incidences of limb pain, oral mucositis, diarrhea, and elevated alanine aminotransferase(ALT) were 13.3%, 13.3%, 6.7%, and 13.3%, respectively. Conclusion Arotinib has a certain effect on advanced ovarian cancer after multiple line chemotherapy, and the adverse reactions can be tolerated by adjusting the dosage.
作者
陈倩
赵秧
康马飞
李碧慧
石洁琼
CHEN Qian;ZHAO Yang;KANG Ma-fei(Department of Medical Oncology,Affiliated Hospital of Guilin Medical University,Guilin 541001,China)
出处
《中国实用医药》
2020年第7期1-3,共3页
China Practical Medicine
关键词
晚期卵巢癌
多线化疗后进展
安罗替尼
分子靶向治疗
Advanced ovarian cancer
Progress after multi-line cheomotherapy
Anlotinib
Molecular targeted therapy
